Reshaping neuroimmunology: diagnosis and treatment in the era of precision medicine DOI Creative Commons
Giordani Rodrigues dos Passos, Tarso Adoni, María Fernanda Mendes

et al.

Arquivos de Neuro-Psiquiatria, Journal Year: 2023, Volume and Issue: 81(12), P. 1125 - 1133

Published: Dec. 1, 2023

Abstract Precision medicine has revolutionized the field of neuroimmunology, with innovative approaches that characterize diseases based on their biology, deeper understanding factors leading to heterogeneity within same disease, development targeted therapies, and strategies tailor therapies each patient. This review explores impact precision various neuroimmunological conditions, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), optic neuritis, autoimmune encephalitis, immune-mediated neuropathies. We discuss advances in subtyping, recognition novel entities, promising biomarkers, more selective monoclonal antibodies cutting-edge synthetic cell-based immunotherapies disorders. In addition, we analyze challenges related affordability equity implementation these emerging technologies, especially situations limited resources.

Language: Английский

Multiple sclerosis DOI
Dejan Jakimovski, Stefan Bittner, Robert Zivadinov

et al.

The Lancet, Journal Year: 2023, Volume and Issue: 403(10422), P. 183 - 202

Published: Nov. 7, 2023

Language: Английский

Citations

181
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting DOI Creative Commons
Marc Charabati, Michael A. Wheeler, Howard L. Weiner

et al.

Cell, Journal Year: 2023, Volume and Issue: 186(7), P. 1309 - 1327

Published: March 1, 2023

Language: Английский

Citations

120
Microglia in multiple sclerosis: Protectors turn destroyers DOI Creative Commons
V. Wee Yong

Neuron, Journal Year: 2022, Volume and Issue: 110(21), P. 3534 - 3548

Published: July 25, 2022

Language: Английский

Citations

90
Lanthanide porphyrinoids as molecular theranostics DOI
Guoqing Jin, Calvin V. Chau, Jonathan F. Arambula

et al.

Chemical Society Reviews, Journal Year: 2022, Volume and Issue: 51(14), P. 6177 - 6209

Published: Jan. 1, 2022

This Review summarises the history and ‘state-of-the-art’ development of lanthanide (Ln) porphyrinoids as theranostic agents. Applications such near-infrared (NIR) fluorescence imaging (FL), magnetic resonance (MRI), radiotherapy, chemotherapy phototheranostics will be discussed.

Language: Английский

Citations

59
Positron Emission Tomography with [18F]‐DPA‐714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression DOI Creative Commons
Mariem Hamzaoui, J. Garcia, Giacomo Boffa

et al.

Annals of Neurology, Journal Year: 2023, Volume and Issue: 94(2), P. 366 - 383

Published: April 11, 2023

To determine the prognostic value of persisting neuroinflammation in multiple sclerosis (MS) lesions, we developed a 18 kDa-translocator-protein-positron emission tomography (PET) -based classification each lesion according to innate immune cell content and localization. We assessed respective predictive phenotype diffuse inflammation on atrophy disability progression over 2 years.Thirty-six people with MS (disease duration 9 ± 6 years; 12 relapsing-remitting, 13 secondary-progressive, 11 primary-progressive) 19 healthy controls (HCs) underwent dynamic [18 F]-DPA-714-PET. At baseline after years, patients also magnetic resonance imaging (MRI) neurological examination. Based threshold significant defined by comparison F]-DPA-714 binding between HCs, white matter lesions were classified as homogeneously active (active center), rim-active (inactive center periphery), or nonactive. Longitudinal cortical was measured using Jacobian integration.Patients had higher normal-appearing (NAWM) cortex than HCs (respective standardized effect size = 1.15, 0.89, p 0.003 < 0.001). Out 1,335 non-gadolinium-enhancing 53% homogeneously-active (median 17 per patient MS), 6% 1 41% non-active 14 MS). The number homogenously-active strongest predictor longitudinal changes, associating (β 0.49, 0.023) Expanded Disability Status Scale (EDSS) changes 0.35, years. NAWM not associated volumetric clinical changes.The F]-DPA-714-PET revealed that an unexpectedly high proportion have smoldering component, which predicts progression. This suggests following acute phase, most develop chronic inflammatory promoting neurodegeneration ANN NEUROL 2023;94:366-383.

Language: Английский

Citations

41
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis DOI Creative Commons
Vito A. G. Ricigliano, Céline Louapre,

Émilie Poirion

et al.

Neurology Neuroimmunology & Neuroinflammation, Journal Year: 2022, Volume and Issue: 9(6)

Published: Oct. 13, 2022

Objectives

To explore how e-cigarettes are being promoted at point of sale in the UK and retailers perceive market trends.

Setting

Fixed retail outlets subject to a ban on display tobacco products.

Participants

Observational audit all stores selling products (n=96) 4 Scottish communities, conducted over 2 waves 12 months apart (2013–2014), qualitative interviews with small (n=25) matched communities.

Primary secondary outcome measures

The measured e-cigarette characteristics, advertising materials proximity other products, differences by area-level disadvantage. Interviews explored retailers' perceptions opportunities risks, customer responses.

Results

number point-of-sale units brands displayed increased between waves. E-cigarettes were close interest children 36% stores. Stores more affluent areas less likely have external than those deprived areas. Although delivered high profit margins, confused diversity uncertain sector9s viability. Some customers perceived purchase as cessation aids, others, particularly low-income smokers, cheaper adjunct conventional tobacco.

Conclusions

E-cigarette displays months, potential cause for concern given their lack regulation. Further scrutiny is needed content effects such advertising, potentially normalising placing next children.

Language: Английский

Citations

40
Periventricular remyelination failure in multiple sclerosis: a substrate for neurodegeneration DOI Creative Commons
Mattéo Tonietto,

Émilie Poirion,

Andrea Lazzarotto

et al.

Brain, Journal Year: 2022, Volume and Issue: 146(1), P. 182 - 194

Published: Sept. 10, 2022

In multiple sclerosis, spontaneous remyelination is generally incomplete and heterogeneous across patients. A high heterogeneity in may also exist lesions within the same individual, suggesting presence of local factors interfering with myelin regeneration. this study we explored vivo regional distribution repair investigated its relationship neurodegeneration. We first took advantage binding property amyloid radiotracer 11C-PiB to conduct a longitudinal PET an original cohort 19 participants relapsing-remitting form followed-up over period 1-4 months. then replicated our results on independent 40 people sclerosis 1 year magnetization transfer imaging, MRI metrics sensitive content. For each imaging method, voxel-wise maps content changes were generated according modality-specific thresholds. demonstrated selective failure periventricular white matter both cohorts. replication cohort, estimated that probability demyelinated voxels remyelinate follow-up increased significantly as function distance from ventricular CSF. Enlarged choroid plexus, recently discovered biomarker linked neuroinflammation, was found be associated two cohorts (r = -0.79, P 0.0018; r -0.40, 0.045, respectively), role brain-CSF barrier affecting surrounding tissues. cohorts, lower thalamic volume 0.86, < 0.0001; 0.33; 0.069, marker Interestingly, showed association between cortical atrophy mediated by number cortex-derived tracts passing through lesions, especially patients at stage. Our findings demonstrate lesion proximity ventricles support hypothesis combination large connecting areas key mechanism contributing damage sclerosis.

Language: Английский

Citations

39
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders DOI Creative Commons

Yi Song,

Jian Li, Yuzhang Wu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Oct. 4, 2024

Autoimmune disorders are characterized by aberrant T cell and B reactivity to the body's own components, resulting in tissue destruction organ dysfunction. diseases affect a wide range of people many parts world have become one major concerns public health. In recent years, there been substantial progress our understanding epidemiology, risk factors, pathogenesis mechanisms autoimmune diseases. Current approved therapeutic interventions for mainly non-specific immunomodulators may cause broad immunosuppression that leads serious adverse effects. To overcome limitations immunosuppressive drugs treating diseases, precise target-specific strategies urgently needed. date, significant advances made immune tolerance, offering new avenue developing antigen-specific immunotherapies These approaches shown great potential various preclinical animal models recently evaluated clinical trials. This review describes common manifestation with focus on typical including multiple sclerosis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, sjögren's syndrome. We discuss current therapeutics developed this field, highlight use nanomaterials mRNA vaccine techniques induce tolerance.

Language: Английский

Citations

13
An update on the role of magnetic resonance imaging in predicting and monitoring multiple sclerosis progression DOI Creative Commons
Piriyankan Ananthavarathan, Nitin Sahi, Declan Chard

et al.

Expert Review of Neurotherapeutics, Journal Year: 2024, Volume and Issue: 24(2), P. 201 - 216

Published: Jan. 18, 2024

Introduction While magnetic resonance imaging (MRI) is established in diagnosing and monitoring disease activity multiple sclerosis (MS), its utility predicting progression less clear.

Language: Английский

Citations

11
The protein kinase C modulator bryostatin-1 therapeutically targets microglia to attenuate neuroinflammation and promote remyelination DOI
Payam Gharibani, Efrat Abramson, Shruthi Shanmukha

et al.

Science Translational Medicine, Journal Year: 2025, Volume and Issue: 17(780)

Published: Jan. 8, 2025

In multiple sclerosis (MS), microglia and macrophages within the central nervous system (CNS) play an important role in determining balance among demyelination, neurodegeneration, myelin repair. Phagocytic regenerative functions of these CNS innate immune cells support remyelination, whereas chronic maladaptive inflammatory activation promotes lesion expansion disability, particularly progressive forms MS. No currently approved drugs convincingly target CNS, contributing to lack therapies aimed at promoting remyelination slowing disease progression for individuals with Here, we found that protein kinase C (PKC)–modulating drug bryostatin-1 (bryo-1), a CNS-penetrant compound established human safety profile, shifts transcriptional programs CNS-associated from proinflammatory phenotype vitro vivo. Treatment bryo-1 stimulated scavenger pathways, phagocytosis, secretion factors prevented neuroinflammatory reactive astrocytes while also neuroaxonal health oligodendrocyte differentiation. line findings, systemic treatment mice augmented after focal demyelinating injury. Our results demonstrate potential possibly wider class PKC modulators as myelin-regenerative supportive agents MS other neurologic diseases.

Language: Английский

Citations

1